Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation

Division

North Florida

Hospital

Osceola Regional Medical Center

Document Type

Case Report

Publication Date

7-26-2024

Keywords

azacitidine, azacytidine, peripheral t-cell lymphoma not otherwise specified, ptcl, ptcl-nos, t-cell lymphoma

Disciplines

Hemic and Lymphatic Diseases | Internal Medicine | Medicine and Health Sciences | Neoplasms

Abstract

Peripheral T-cell lymphomas (PTCLs) are an aggressive form of non-Hodgkin lymphomas. PTCLs have multiple subtypes, with PTCL not otherwise specified (PTCL-NOS) being the most common. This subtype usually has a high rate of relapse. Making an accurate diagnosis requires molecular genetic analyses, histopathological examination, and immunophenotyping. Treatment for PTCL traditionally starts with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). We present a case of a patient with PTCL-NOS who progressed despite multiple treatment regimens, including both traditional and novel therapeutic agents, and finally achieved good results with azacytidine, selected based on a

Publisher or Conference

Cureus

Link to Full Text

Share

COinS